Efficacy and safety of HRS-7535, an oral small-molecule GLP-1…
An oral GLP-1 drug reduced kidney protein leakage by nearly a third in diabetics with kidney disease, adding hope for protecting kidneys beyond current standard treatments.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Multiorgan Outcomes Following BNT162b2 mRNA Vaccination vs SARS-CoV-2 Infection
COVID-19 vaccination reduced heart-related deaths by 77% and major cardiovascular events by 65-76% compared to infection, confirming strong cardiac protection beyond preventing the virus itself.
NONEReal-world outcomes of triplet therapy with gilteritinib, azacitidine…
A three-drug combination achieved complete remission in nearly all treatment-resistant acute leukemia patients, with half remaining in long-term remission after a median of three years.
NONEHemophagocytic lymphohistiocytosis-like syndrome after CD19-directed…
This registry documents when immunotherapy causes a serious inflammatory reaction, helping doctors recognize and manage a major safety concern in blood cancer CAR-T cell therapy.
NONEDual-targeting pharmacological UFMylation inhibition reprograms tumor…
A novel approach targeting tumor cells' stress response achieved tumor-free survival in two-thirds of brain cancer mice with lasting immune protection against recurrence.